Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactiplantibacillus plantarum WJL
- Development stage
- Preclinical
- Lead developer
- TargEDys
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactiplantibacillus plantarum WJL is a precision probiotic strain developed by TargEDys in collaboration with the Functional Genomics Institute of Lyon[1]. It is a gram-positive lactic acid bacterium selected for its ability to optimize amino acid absorption through stimulation of the somatotropic axis[1]. The strain has been investigated for applications including children's growth, elderly bone and muscle mass, and sports nutrition[1]. Key mechanisms of action include: - Modulation of gut microbiota composition and diversity[2] - Improvement of lipid metabolism and insulin sensitivity[2] - Enhancement of intestinal barrier function through tight junction protein expression - Production of antimicrobial compounds to inhibit pathogenic bacteria growth - Stimulation of amino acid absorption via the somatotropic axis The strain exhibits genetic and metabolic flexibility, allowing it to thrive in various gastrointestinal environments and fermented food products[3].
- Other names
- Lactobacillus plantarum WJL (former nomenclature)
02
Targets
TLR2 (Toll-like Receptor 2)EIF2AK4 (Eukaryotic translation initiation factor 2-alpha kinase 4)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on Lactiplantibacillus plantarum WJL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactiplantibacillus plantarum WJL.